WO2016091181A1 - 用于免疫中的有效抗体生产的新颖蛋白质结构 - Google Patents
用于免疫中的有效抗体生产的新颖蛋白质结构 Download PDFInfo
- Publication number
- WO2016091181A1 WO2016091181A1 PCT/CN2015/096949 CN2015096949W WO2016091181A1 WO 2016091181 A1 WO2016091181 A1 WO 2016091181A1 CN 2015096949 W CN2015096949 W CN 2015096949W WO 2016091181 A1 WO2016091181 A1 WO 2016091181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- peptide
- amino acid
- seq
- acid sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 94
- 102000004169 proteins and genes Human genes 0.000 title claims description 93
- 230000003053 immunization Effects 0.000 title description 16
- 238000002649 immunization Methods 0.000 title description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 172
- 108091007433 antigens Proteins 0.000 claims abstract description 53
- 102000036639 antigens Human genes 0.000 claims abstract description 53
- 239000000427 antigen Substances 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 42
- 230000028993 immune response Effects 0.000 claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 claims abstract description 18
- 235000018102 proteins Nutrition 0.000 claims description 79
- 150000001413 amino acids Chemical class 0.000 claims description 63
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 18
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 18
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 18
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 18
- 229960000310 isoleucine Drugs 0.000 claims description 18
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 18
- 239000004474 valine Substances 0.000 claims description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 241000712431 Influenza A virus Species 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 241000588832 Bordetella pertussis Species 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 241000710886 West Nile virus Species 0.000 claims description 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000713196 Influenza B virus Species 0.000 claims 1
- 241000713297 Influenza C virus Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000005090 green fluorescent protein Substances 0.000 description 182
- 210000004027 cell Anatomy 0.000 description 75
- 108020001507 fusion proteins Proteins 0.000 description 58
- 102000037865 fusion proteins Human genes 0.000 description 58
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 50
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 29
- 238000002965 ELISA Methods 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 22
- 239000002609 medium Substances 0.000 description 19
- 239000002671 adjuvant Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 238000002523 gelfiltration Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 13
- 230000004927 fusion Effects 0.000 description 12
- 230000004727 humoral immunity Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000007927 intramuscular injection Substances 0.000 description 12
- 238000010255 intramuscular injection Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 108010040721 Flagellin Proteins 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 8
- 101150033606 Grk5 gene Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 210000004748 cultured cell Anatomy 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 7
- 230000028996 humoral immune response Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 101800001728 Nsp1 Proteins 0.000 description 6
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 238000012270 DNA recombination Methods 0.000 description 4
- 108010056586 G-Protein-Coupled Receptor Kinase 5 Proteins 0.000 description 4
- 102000004192 G-Protein-Coupled Receptor Kinase 5 Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000012754 cardiac puncture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007893 endotoxin activity Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 description 3
- 239000012480 LAL reagent Substances 0.000 description 3
- 101100495074 Mus musculus Ccl2 gene Proteins 0.000 description 3
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 241000710961 Semliki Forest virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229950004243 cacodylic acid Drugs 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 229920004439 Aclar® Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000011537 Coomassie blue staining Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101900330356 Influenza A virus Matrix protein 2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 101710144127 Non-structural protein 1 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 description 1
- 241000607361 Salmonella enterica subsp. enterica Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (15)
- 一种增进免疫应答的方法,其特征在于,包含:结合两亲性肽与抗原以形成抗原复合物合成物;以及将所述抗原复合物合成物给予受试者。
- 如权利要求1所述的方法,其特征在于,所述两亲性肽范围涵盖从4至45个氨基酸。
- 如权利要求2所述的方法,其特征在于,所述两亲性肽包含SEQ ID NO:1的氨基酸序列、SEQ ID NO:2的氨基酸序列、或SEQ ID NO:3的氨基酸序列。
- 如权利要求2所述的方法,其特征在于,所述两亲性肽包含含有A1B1B2A2及/或A3B3B4B5A4基序的氨基酸序列,其中,A1、A2、A3及A4是每个个别地选自由精氨酸(R)及赖氨酸(K)所组成的群组;B1是选自由赖氨酸(K)、精氨酸(R)、异亮氨酸(I)、亮氨酸(L)及缬氨酸(V)所组成的群组;B2是选自由异亮氨酸(I)、亮氨酸(L)、缬氨酸(V)、苯基丙氨酸(F)、酪氨酸(Y)、及色氨酸(W)所组成的群组;B3是选自由异亮氨酸(I)、亮氨酸(L)及缬氨酸(V)所组成的群组;B4是选自由苯基丙氨酸(F)、色氨酸(W)及酪氨酸(Y)所组成的群组;以及B5是选自由苯基丙氨酸(F)、酪氨酸(Y)、色氨酸(W)、苏氨酸(T)、半胱氨酸(C)及丝氨酸(S)组成的群组。
- 如权利要求4所述之方法,其特征在于,所述两亲性肽包含SEQ ID NO:4的氨基酸序列、SEQ ID NO:5的氨基酸序列、SEQ ID NO:6的氨基酸序列、SEQ ID NO:7的氨基酸序列、SEQ ID NO:8的氨基酸序列、SEQ ID NO:9的氨基酸序列、SEQ ID NO:10 的氨基酸序列或SEQ ID NO:11的氨基酸序列。
- 如权利要求1所述之方法、其特征在于,所述抗原是选自由A型流感病毒、B型流感病毒、C型流感病毒、登革病毒、人类乳突病毒、甲型肝炎病毒、乙型肝炎病毒、丙型肝炎病毒、水痘带状疱疹病毒、巨细胞病毒、埃博拉病毒、B型流感嗜血杆菌、幽门螺杆菌、单纯性疱疹病毒1及2型、疟原虫物种、麻疹病毒、中东呼吸综合症冠状病毒、腮腺炎病毒、百日咳博德特式杆菌、小儿麻痹病毒、狂犬病病毒、呼吸道合胞体病毒、轮状病毒、风疹病毒、严重急性呼吸综合症冠状病毒、破伤风杆菌、结核杆菌、西尼罗河病毒、肺炎链球菌、金黄色葡萄球菌、艰难梭菌、脑膜炎球菌以及沙门氏杆菌所组成的群组的病原体的一部份。
- 如权利要求1所述之方法,其特征在于,所述抗原是选自由低聚糖、多肽、蛋白质、多聚糖、肽及其组合所组成的群组。
- 如权利要求1所述之方法,其特征在于,所述受试者是温血动物。
- 一种抗原复合物合成物,其特征在于,包含:A1B1B2A2及/或A3B3B4B5A4基序;第一肽,接合至所述A1B1B2A2及/或A3B3B4B5A4基序的N-端;第二肽,接合至所述A1B1B2A2及/或A3B3B4B5A4基序的C-端;抗原,共价接合至所述第一肽或所述第二肽,其中,A1、A2、A3及A4是每个个别地选自由精氨酸(R)及赖氨酸(K)所组成的群组;B1是选自由赖氨酸(K)、精氨酸(R)、异亮氨酸(I)、亮氨酸(L)及缬氨酸(V)所组成的群组;B2是选自由异亮氨酸(I)、亮氨酸(L)、缬氨酸(V)、苯基丙氨酸(F)、酪氨酸(Y)、及色氨酸(W)所组成的群组;B3是选自由异亮氨酸(I)、亮氨酸(L)及缬氨酸(V)所组成的群组;B4是选自由苯基丙氨酸(F)、色氨酸(W)及酪氨酸(Y)所组成的群组;以及B5是选自由苯基丙氨酸(F)、酪氨酸(Y)、色氨酸(W)、苏氨酸(T)、半胱氨酸(C)及丝氨酸(S)组成的群组;且所述A1B1B2A2及/或A3B3B4B5A4基序、所述第一肽以及所述第二肽形成两亲性螺旋二级结构。
- 如权利要求9所述的抗原复合物合成物,其特征在于,所述第一肽范围涵盖从0至20个氨基酸,且所述第二肽范围涵盖从0至20个氨基酸。
- 如权利要求9所述的抗原复合物合成物,其特征在于,所述抗原是选自由低聚糖、多肽、蛋白质、多聚糖、肽以及其组合所组成的群组。
- 一种增进抗原递送的方法,其特征在于,包含:给予抗原复合物合成物予受试者,其中所述抗原复合物合成物包含:A1B1B2A2及/或A3B3B4B5A4基序;第一肽,接合至所述A1B1B2A2及/或A3B3B4B5A4基序的N-端;第二肽,接合至所述A1B1B2A2及/或A3B3B4B5A4基序的C-端;抗原,共价接合至所述第一肽或所述第二肽,其中:A1、A2、A3及A4是每个个别地选自由精氨酸(R)及赖氨酸(K)所组成的群组;B1是选自由赖氨酸(K)、精氨酸(R)、异亮氨酸(I)、亮氨酸(L)及缬氨酸(V)所组成的群组;B2是选自由异亮氨酸(I)、亮氨酸(L)、缬氨酸(V)、苯基丙氨酸(F)、酪氨酸(Y)、及色氨酸(W)所组成的群组;B3是选自由异亮氨酸(I)、亮氨酸(L)及缬氨酸(V)所组成的群组;B4是选自由苯基丙氨酸(F)、色氨酸(W)及酪氨酸(Y)所组成的群组;以及B5是选自由苯基丙氨酸(F)、酪氨酸(Y)、色氨酸(W)、苏氨酸(T)、半胱氨酸(C)及丝氨酸(S)组成的群组;且所述A1B1B2A2及/或A3B3B4B5A4基序、所述第一肽以及所述第二肽形成两亲性螺旋二级结构。
- 如权利要求12所述的方法,其特征在于,所述第一肽范围涵盖从0至20个氨基酸,且所述第二肽范围涵盖从0至20个氨基酸。
- 如权利要求12所述的方法,其特征在于,所述抗原是选自由低聚糖、多肽、蛋白质、多聚糖、肽及其组合所组成的群组。
- 一种两亲性肽,其特征在于,包含:SEQ ID NO:1的氨基酸序列、SEQ ID NO:2的氨基酸序列、、SEQ ID NO:3的氨基酸序列、SEQ ID NO:4的氨基酸序列、SEQ ID NO:5的氨基酸序列、SEQ ID NO:6的氨基酸序列、SEQ ID NO:7的氨基酸序列、SEQ ID NO:8的氨基酸序列、SEQ ID NO:9的氨基酸序列、SEQ ID NO:10的氨基酸序列或SEQ ID NO:11的氨基酸序列。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15868210.4A EP3231441A4 (en) | 2014-12-10 | 2015-12-10 | Novel protein structure produced by effective antibody used for immunization |
AU2015360107A AU2015360107A1 (en) | 2014-12-10 | 2015-12-10 | Novel protein structure produced by effective antibody used for immunization |
US15/534,756 US20180161425A1 (en) | 2014-12-10 | 2015-12-10 | Novel protein structure used for efficient antibody production in immunization |
CN201580061360.5A CN107106668A (zh) | 2014-12-10 | 2015-12-10 | 用于免疫中的有效抗体生产的新颖蛋白质结构 |
JP2017549573A JP2018500389A (ja) | 2014-12-10 | 2015-12-10 | 効率的な抗体産生のための免疫化に使用される新規なタンパク質構造 |
CA2970211A CA2970211A1 (en) | 2014-12-10 | 2015-12-10 | Novel protein structure produced by effective antibody used for immunization |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462090180P | 2014-12-10 | 2014-12-10 | |
US62/090,180 | 2014-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016091181A1 true WO2016091181A1 (zh) | 2016-06-16 |
Family
ID=56106724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/096949 WO2016091181A1 (zh) | 2014-12-10 | 2015-12-10 | 用于免疫中的有效抗体生产的新颖蛋白质结构 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20180161425A1 (zh) |
EP (1) | EP3231441A4 (zh) |
JP (1) | JP2018500389A (zh) |
CN (1) | CN107106668A (zh) |
AU (1) | AU2015360107A1 (zh) |
CA (1) | CA2970211A1 (zh) |
CL (1) | CL2017001471A1 (zh) |
TW (2) | TWI683668B (zh) |
WO (1) | WO2016091181A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112912386A (zh) * | 2018-11-02 | 2021-06-04 | 中国医学科学院基础医学研究所 | 基于流感病毒m2蛋白的细胞穿透肽 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI657824B (zh) * | 2017-12-29 | 2019-05-01 | 財團法人生物技術開發中心 | 抗流感之通用疫苗 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1503628A (zh) * | 2001-02-15 | 2004-06-09 | ���ٸ��� | 穿细胞肽在产生抗肿瘤免疫力上的用途 |
WO2015164798A1 (en) * | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306912A3 (en) * | 1987-09-08 | 1989-07-05 | Albany Medical College | Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same. |
WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
GB0613977D0 (en) * | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
WO2010009277A2 (en) * | 2008-07-15 | 2010-01-21 | Novartis Ag | Immunogenic amphipathic peptide compositions |
JP4797149B2 (ja) * | 2009-10-23 | 2011-10-19 | 研爾 奥田 | インフルエンザウイルスに対するベクターワクチン |
US9657064B2 (en) * | 2012-09-13 | 2017-05-23 | Les Hopitaux Universitaires De Geneve | Cell penetrating peptides |
EP2916873B1 (en) * | 2012-11-07 | 2017-07-26 | Council of Scientific & Industrial Research | Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules |
-
2015
- 2015-12-10 US US15/534,756 patent/US20180161425A1/en not_active Abandoned
- 2015-12-10 TW TW107103648A patent/TWI683668B/zh active
- 2015-12-10 EP EP15868210.4A patent/EP3231441A4/en not_active Withdrawn
- 2015-12-10 JP JP2017549573A patent/JP2018500389A/ja active Pending
- 2015-12-10 TW TW104141435A patent/TWI623322B/zh not_active IP Right Cessation
- 2015-12-10 AU AU2015360107A patent/AU2015360107A1/en not_active Abandoned
- 2015-12-10 CA CA2970211A patent/CA2970211A1/en not_active Abandoned
- 2015-12-10 CN CN201580061360.5A patent/CN107106668A/zh active Pending
- 2015-12-10 WO PCT/CN2015/096949 patent/WO2016091181A1/zh active Application Filing
-
2017
- 2017-06-08 CL CL2017001471A patent/CL2017001471A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1503628A (zh) * | 2001-02-15 | 2004-06-09 | ���ٸ��� | 穿细胞肽在产生抗肿瘤免疫力上的用途 |
WO2015164798A1 (en) * | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
Non-Patent Citations (20)
Title |
---|
AHOLA, T. ET AL.: "Semliki Forest Virus mRNA Capping Enzyme Requires Association with Anionic Membrane Phospholipids for Activity", THE EMBO JOURNAL, vol. 18, no. 11, 31 December 1999 (1999-12-31), pages 3164 - 3172, XP055454385 * |
BLACK, M. ET AL.: "Self-Assembled Peptide Amphiphile Micelles Containing a Cytotoxic T- Cell Epitope Promote a Protective Immune Response In Vivo", ADV. MATER., vol. 24, 2 May 2012 (2012-05-02), pages 3845 - 3849, XP055454401 * |
BRASS, V. ET AL.: "Structural Determinants for Membrane Association and Dynamic Organization of The Hepatitis C Virus NS3-4A Complex", PNAS, vol. 105, no. 38, 23 September 2008 (2008-09-23), pages 14545 - 14550, XP055454378 * |
DAKAPPAGARI, N.K. ET AL.: "Intracellular Delivery of A Novel Multiepitope Peptide Vaccine by An Amphipathic Peptide Carrier Enhances Cytotoxic T- Cell Responses in HLA-A*201 Mice", J. PEPTIDE RES., vol. 65, 31 December 2005 (2005-12-31), pages 189 - 199, XP002443601, DOI: doi:10.1111/j.1399-3011.2005.00212.x * |
DATABASE GENBANK 12 November 2010 (2010-11-12), "Matrix Protein 2, Partial [Influenza A Virus (A/Ohio/K1130/2006 (H1N1", Database accession no. ACD65196.1 * |
DATABASE GENBANK 13 March 2013 (2013-03-13), "Orf 48 [Ateline Herpesvirus 3", Database accession no. NP 048021.1 * |
DATABASE GENBANK 14 November 2014 (2014-11-14), "Wsv445 [Shrimp White Spot Syndrome Virus", XP055455735, Database accession no. AAL33446.1 * |
DATABASE GENBANK 19 June 2006 (2006-06-19), "GRK5 Protein [Homo sapiens", Database accession no. AAI14449.1 * |
DATABASE GENBANK 2 March 2015 (2015-03-02), "Hypothetical Protein [ANMV-1 Virus", Database accession no. AJP62030.1 * |
DATABASE GENBANK 26 May 2009 (2009-05-26), "Matrix Protein 2, Partial [Influenza A virus (A/Istanbul/30/2009 (H1N1", Database accession no. ACR39353.1 * |
DATABASE GENBANK 30 March 2004 (2004-03-30), "Matrix Protein 2, Partial [Influenza A virus (A/chicken/Chile/4957/02 (H7N3", Database accession no. AAQ77437.1 * |
DATABASE GENBANK 30 May 2008 (2008-05-30), "REP-Associated Protein, Partial [Tomato Yellow Leaf Curl Virus", XP055455739, Database accession no. ABY61014.1 * |
DATABASE GENBANK DATABASE 12 November 2010 (2010-11-12), "Matrix Protein 2, Partial [Influenza A Virus (A/Ohio/K1130/2006 (H1N1", Database accession no. ACD65196.1 * |
DATABASE GENBANK DATABASE 30 March 2004 (2004-03-30), "Matrix Protein 2, Partial [Influenza A Virus (A/chicken/Chile/4957/02 (H7N3", Database accession no. AAQ77437.1 * |
DELISI, C. ET AL.: "T- Cell Antigenic Sites Tend to Be Amphipathic Structures", PROC. NAL. ACAD. SCI. USA, vol. 82, 31 October 1985 (1985-10-31), pages 7048 - 7052, XP055454409 * |
GHOSH, U. ET AL.: "Detection of Closed Influenza Virus Hemagglutinin Fusion Peptide Structures in Membranes by Backbone 13CO-15N Rotational-Echodouble-Resonance Solid-State NMR", J. BIOMOL. NMR, vol. 55, 18 January 2013 (2013-01-18), pages 139 - 146, XP035320285 * |
GUPTA, B. ET AL.: "Intracellular Delivery of Large Molecules and Small Particles by Cell -Penetrating Proteins and Peptides", ADVANCED DRUG DELIVERY REVIEWS, vol. 57, 22 December 2004 (2004-12-22), pages 637 - 651, XP004752192, DOI: doi:10.1016/j.addr.2004.10.007 * |
ROSSMAN, J.S. ET AL.: "Influenza Virus M2 Ion Channel Protein Is Necessary for Filamentous Virion Formation", JOURNAL OF VIROLOGY, vol. 84, no. 10, 31 May 2010 (2010-05-31), pages 5078 - 5088, XP055165548, DOI: doi:10.1128/JVI.00119-10 * |
See also references of EP3231441A4 * |
WANG, RF. ET AL.: "Enhancement of Antitumor Immunity by Prolonging Antigen Presentation on Dendritic Cells", NATURE BIOTECHNOLOGY, vol. 20, 28 February 2002 (2002-02-28), pages 149 - 154, XP002954302, DOI: doi:10.1038/nbt0202-149 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112912386A (zh) * | 2018-11-02 | 2021-06-04 | 中国医学科学院基础医学研究所 | 基于流感病毒m2蛋白的细胞穿透肽 |
CN112912386B (zh) * | 2018-11-02 | 2023-10-20 | 中国医学科学院基础医学研究所 | 基于流感病毒m2蛋白的细胞穿透肽 |
Also Published As
Publication number | Publication date |
---|---|
TWI683668B (zh) | 2020-02-01 |
TW201627005A (zh) | 2016-08-01 |
AU2015360107A1 (en) | 2017-06-29 |
JP2018500389A (ja) | 2018-01-11 |
CA2970211A1 (en) | 2016-06-16 |
US20180161425A1 (en) | 2018-06-14 |
TWI623322B (zh) | 2018-05-11 |
CN107106668A (zh) | 2017-08-29 |
TW201815414A (zh) | 2018-05-01 |
EP3231441A4 (en) | 2018-10-31 |
CL2017001471A1 (es) | 2018-03-02 |
EP3231441A1 (en) | 2017-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11793871B2 (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
WO2020257317A1 (en) | Rationally engineered carrier proteins for vaccines | |
JP2002517249A (ja) | 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強 | |
CN104411328A (zh) | 组合物 | |
WO2016091181A1 (zh) | 用于免疫中的有效抗体生产的新颖蛋白质结构 | |
US9150619B2 (en) | Method of elicting or inducing an immune response | |
TW201502136A (zh) | 疫苗 | |
TW202308685A (zh) | 冠狀病毒和流感病毒組合物及其使用方法 | |
Sazegari et al. | Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice | |
US10300124B2 (en) | Rodent hepadnavirus cores with reduced carrier-specific antigenicity | |
CA2991544A1 (en) | Vaccines for the treatment and prevention of ige mediated diseases | |
Montaner et al. | Ganglioside GM1-binding peptides as adjuvants of antigens inoculated by the intranasal route | |
WO2023064631A1 (en) | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing | |
CN106337038A (zh) | 一种通过转肽酶剪切制备疫苗的方法及其应用 | |
JP2021038159A (ja) | Rage由来ペプチドおよびその使用 | |
CN111658770A (zh) | P14.7蛋白质及其作为疫苗佐剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15868210 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2970211 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017549573 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15534756 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015868210 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015360107 Country of ref document: AU Date of ref document: 20151210 Kind code of ref document: A |